Printer Friendly

Using Genetic Technology to Diagnose Cancer Types in Cats

Each year, as many as 22,000 cats in the U.S. develop sarcomas at the site of a vaccine or other injection. Because these injection site–associated sarcomas (ISASs) are typically more aggressive and prone to recurrence than spontaneous sarcomas that are not injection related, they often require more urgent and radical therapeutic intervention. Distinguishing between ISASs and non-ISASs is essential for optimizing clinical management and outcome for each patient, but at present there are no efficient and definitive means for diagnosis. This study uses state-of-the-art microarray-based technology to identify DNA-based markers that may provide more powerful diagnostic and prognostic tools for evaluating these tumors. These data will highlight cancer-associated gene defects as potential new therapeutic targets and will provide a wealth of comparative data that will advance feline molecular oncology studies.

Dr. Rachael Thomas, North Carolina State University